Skip to main content
SpringerLink
Log in

Cardiac-specific mortality at 5 years higher with ADT

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Neoadjuvant ADT included both a GnRH agonist (depot formulations of leuprolide or goserelin) and an oral nonsteroidal antiandrogen (bicalutamide or flutamide).

Reference

  • Ziehr DR, et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU International : [8 pages], 29 Oct 2014. Available from: URL: http://doi.org/10.1111/bju.12905

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cardiac-specific mortality at 5 years higher with ADT. Reactions Weekly 1527, 9 (2014). https://doi.org/10.1007/s40278-014-4803-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-4803-9

Search

Navigation